Radical Health

Radical Health, based in the US, specializes in harnessing data and AI to deliver personalized oncology reports, empowering patients with clear treatment options derived from extensive health data analysis. Founded in 2024, Radical Health is located in San Francisco, US, and focuses on developing AI-driven personalized oncology solutions. The company raised USD 5. 00 mn in pre-seed funding in December 2025, co-led by Khosla Ventures and Protagonist, with additional support from Headwater Ventures and Transpose Platform Management.

The founder's background and previous entrepreneurial endeavors are not disclosed. Radical Health specializes in providing personalized oncology reports that leverage AI technology to synthesize extensive patient data, including medical histories, clinical notes, lab results, and genetic data. Their core offering is a detailed, personalized treatment report designed to empower patients by clarifying their treatment options and potential pathways based on the latest medical research and anonymized patient journeys. This product targets individuals navigating complex cancer diagnoses, such as breast, prostate, and lung cancer, and is particularly aimed at patients seeking second opinions or alternative treatment options.

The services are currently offered free of charge to an initial group of users to gather feedback, indicating a focus on refinement and improvement prior to broader market release, specifically in the United States, with plans for international expansion as the platform matures. Radical Health's revenue generation primarily revolves around the provision of personalized oncology reports. Currently, these reports are offered free to early users, facilitating user acquisition and feedback for platform enhancement. As the company progresses beyond its initial offering phase, potential revenue structures may include subscription models for ongoing personalized health insights and partnerships with healthcare providers.

Future transactional structures may involve direct-to-consumer sales, allowing patients to access reports that guide their treatment discussions with healthcare professionals. Specific pricing plans have not been disclosed, however, the personalized oncology report serves as the cornerstone of the company’s service offerings. In December 2025, Radical Health raised USD 5. 00 mn in pre-seed funding, which will be utilized to advance its AI-based platform providing personalized cancer treatment recommendations and to foster collaborations with leading healthcare organizations.

The company is focused on developing additional products, with plans for broader market release following its initial feedback phase. Radical Health is also exploring opportunities to expand its services into international markets as its platform matures.